Brian Hubbard is director of the Therapeutics Projects Group (TPG) at the Broad Institute of MIT and Harvard.
Under his leadership, and drawing on the Broad’s multiple programs and platforms, his group aspires to transform the process of drug discovery and the treatment of human disease by developing and applying novel drug discovery technologies; targeting novel classes of protein targets, generally viewed as “undruggable”; targeting novel mechanisms emerging from studies of human biology; and working in an open, collaborative environment to establish proofs of concept.
Hubbard brings extensive knowledge of drug discovery and development. Before coming to the Broad, he was Senior Director of Cardiovascular Diseases at Merck, where he was responsible for strategy and execution of research. His focus was primarily atherosclerosis research. While at Merck, Hubbard was also part of a core team that developed a strategic plan for restructuring basic research in the pharmaceutical industry.
Prior to his work at Merck, Hubbard was Director of Cardiovascular and Metabolism Research at Novartis Institutes for Biomedical Research and did research into metabolic diseases and obesity at Millennium Pharmaceuticals.
Hubbard received his B.S. in chemistry from The College of William and Mary and a Ph.D. in chemistry from the University of Illinois Champaign-Urbana. He did postdoctoral research in biochemistry and antibiotics at Harvard Medical School.Last updated date: May, 2013